1. Home
  2. SENEB vs DNTH Comparison

SENEB vs DNTH Comparison

Compare SENEB & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SENEB
  • DNTH
  • Stock Information
  • Founded
  • SENEB 1949
  • DNTH 2015
  • Country
  • SENEB United States
  • DNTH United States
  • Employees
  • SENEB N/A
  • DNTH N/A
  • Industry
  • SENEB Packaged Foods
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • SENEB Consumer Staples
  • DNTH Health Care
  • Exchange
  • SENEB Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • SENEB 720.7M
  • DNTH 606.2M
  • IPO Year
  • SENEB N/A
  • DNTH N/A
  • Fundamental
  • Price
  • SENEB $103.87
  • DNTH $20.45
  • Analyst Decision
  • SENEB
  • DNTH Strong Buy
  • Analyst Count
  • SENEB 0
  • DNTH 8
  • Target Price
  • SENEB N/A
  • DNTH $53.00
  • AVG Volume (30 Days)
  • SENEB 596.0
  • DNTH 372.6K
  • Earning Date
  • SENEB 08-07-2025
  • DNTH 08-07-2025
  • Dividend Yield
  • SENEB N/A
  • DNTH N/A
  • EPS Growth
  • SENEB N/A
  • DNTH N/A
  • EPS
  • SENEB 5.90
  • DNTH N/A
  • Revenue
  • SENEB $1,578,887,000.00
  • DNTH $6,524,000.00
  • Revenue This Year
  • SENEB N/A
  • DNTH N/A
  • Revenue Next Year
  • SENEB N/A
  • DNTH N/A
  • P/E Ratio
  • SENEB $17.33
  • DNTH N/A
  • Revenue Growth
  • SENEB 8.25
  • DNTH 102.36
  • 52 Week Low
  • SENEB $57.51
  • DNTH $13.37
  • 52 Week High
  • SENEB $107.99
  • DNTH $32.27
  • Technical
  • Relative Strength Index (RSI)
  • SENEB 66.31
  • DNTH 59.38
  • Support Level
  • SENEB $101.00
  • DNTH $18.86
  • Resistance Level
  • SENEB $94.02
  • DNTH $20.86
  • Average True Range (ATR)
  • SENEB 0.15
  • DNTH 1.39
  • MACD
  • SENEB -0.16
  • DNTH 0.19
  • Stochastic Oscillator
  • SENEB 48.50
  • DNTH 54.59

About SENEB Seneca Foods Corp. Class B

Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: